Lead Product(s) : Telotristat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TerSera Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Telotristat With Lutathera in Neuroendocrine Tumors
Details : Telotristat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : Telotristat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TerSera Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable